MCM
M28 Capital Management Portfolio holdings
AUM
$58.6M
This Quarter Return
+7.35%
1 Year Return
+32.71%
3 Year Return
+247.5%
5 Year Return
–
10 Year Return
–
AUM
$95.8M
AUM Growth
+$95.8M
(+7.4%)
Cap. Flow
+$103K
Cap. Flow
% of AUM
0.11%
Top 10 Holdings %
Top 10 Hldgs %
99.15%
Holding
13
New
–
Increased
3
Reduced
5
Closed
1
Top Buys
| 1 |
Invivyd
IVVD
|
$8.92M |
| 2 |
BridgeBio Pharma
BBIO
|
$468K |
| 3 |
Curis
CRIS
|
$167K |
Top Sells
| 1 |
VERV
Verve Therapeutics
VERV
|
$3.12M |
| 2 |
TG Therapeutics
TGTX
|
$2.29M |
| 3 |
Atara Biotherapeutics
ATRA
|
$2.1M |
| 4 |
Wave Life Sciences
WVE
|
$1.08M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$798K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Invivyd
IVVD
$204M
| $28.9M | 30.22% | 9,248,250 +2,850,000 | +45% | +$8.92M |
|
|
2
Wave Life Sciences
WVE
$1.53B
| $28.8M | 30.08% | 7,982,204 -300,000 | -4% | -$1.08M |
|
|
3
Rocket Pharmaceuticals
RCKT
$354M
| $10.6M | 11.09% | 665,880 -50,000 | -7% | -$798K |
|
4
Stoke Therapeutics
STOK
$1.08B
| $6.71M | 7% | 522,550 -4,600 | -0.9% | -$59.1K |
|
|
5
BridgeBio Pharma
BBIO
$9.89B
| $5.1M | 5.33% | 513,300 +47,100 | +10% | +$468K |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.27M | 4.46% | 61,200 | – | – |
|
|
7
Curis
CRIS
$20.9M
| $3.14M | 3.27% | 4,482,142 +238,849 | +6% | +$167K |
|
|
VERV
8
DELISTED
Verve Therapeutics
VERV
| $3.01M | 3.14% | 87,600 -90,900 | -51% | -$3.12M |
|
9
Leap Therapeutics
LPTX
$12M
| $2.35M | 2.45% | 2,664,400 | – | – |
|
|
10
TG Therapeutics
TGTX
$4.65B
| $2.01M | 2.09% | 338,800 -387,400 | -53% | -$2.29M |
|
11
ProQR Therapeutics
PRQR
$237M
| $745K | 0.78% | 1,001,800 | – | – |
|
|
NEXI
12
DELISTED
NexImmune, Inc. Common Stock
NEXI
| $74K | 0.08% | 133,442 | – | – |
|
|
13
Atara Biotherapeutics
ATRA
$84.6M
| – | – | -269,253 | Closed | -$2.1M |
|